Arcturus Therapeutics Holdings Inc.
ARCT · XNASCIK 1768224fmd_1H8CGHJSQDPV3Y9YNDX7AHSYF5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 34 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 16 | 21 | 10 | 12 | 206 | 167 | 152 | 82 |
| Research and development | 17 | 34 | 58 | 174 | 148 | 192 | 195 | 112 |
| Total operating expenses | 38 | 46 | 81 | 215 | 194 | 245 | 248 | 158 |
| Operating income | (22) | (26) | (72) | (203) | 12 | (78) | (96) | (76) |
| Other non-operating income (expense) | 0 | (0) | (0) | (2) | (0) | 17 | 15 | 10 |
| Income before taxes | (22) | (26) | (72) | (204) | 11 | (28) | (81) | (66) |
| Income tax expense | – | – | – | – | 1 | 2 | (0) | – |
| Net income from continuing operations | – | – | – | – | 9 | (30) | (81) | – |
| Net income | (22) | (26) | (72) | (204) | 9 | (30) | (81) | (66) |